



PRESS RELEASE

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference

Marseille, France, January 6, 2022 – [ImCheck Therapeutics](https://www.imchecktherapeutics.com) announced today that its Chief Executive Officer, Pierre d'Epenoux, will present a corporate overview on Monday, January 10th at 7:30 am Eastern Time/13:30 Central European Time during the 40th Annual J. P. Morgan Healthcare Conference being held virtually from January 10 - 13, 2022.

About IMCHECK THERAPEUTICS

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's "first-in-class" activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck's antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in $\gamma\delta$ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.

For further information on ImCheck: <http://www.imchecktherapeutics.com> and [@ImCheckThx](https://twitter.com/ImCheckThx)

Press contacts

US and EU

Trophic Communications

Gretchen Schweitzer
+49 (0) 172 861 8540
imcheck@trophic.eu

France

ATCG PARTNERS

Céline Voisin
+33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39
imcheck@atcg-partners.com